PMID- 7698172
OWN - NLM
STAT- MEDLINE
DCOM- 19950428
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 264
IP  - 3
DP  - 1994 Nov 3
TI  - Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and 
      serotonin neurotoxicity by 5-HT2 receptor agonists.
PG  - 325-30
AB  - The effects of the 5-HT2 receptor agonists 
      1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and 
      5-methoxy-N,N-dimethyltryptamine (5-MeODMT) on 3,4-methylenedioxymethamphetamine 
      (MDMA)-induced dopamine release and 5-HT depletion in the striatum were studied. 
      The MDMA-induced increase in the extracellular concentration of dopamine in the 
      striatum was enhanced significantly in rats treated with either DOI (2 mg/kg, 
      ip.) or 5-MeODMT (15 mg/kg, ip.), as assessed using in vivo microdialysis. 
      Neither DOI nor 5-MeODMT alone altered the extracellular concentration of 
      dopamine in the striatum. The striatal concentration of 5-HT was decreased, but 
      not significantly, 7 days following a single administration of MDMA (10 mg/kg, 
      sc.). However, 7 days following the concomitant treatment with DOI and MDMA the 
      striatal concentration of 5-HT was significantly less than that in rats treated 
      with MDMA alone or the vehicle-treated controls. It is concluded that activation 
      of 5-HT2 receptors is an important determinant of the acute increase in 
      extracellular dopamine and, consequently, the long-term depletion of brain 5-HT 
      produced by MDMA.
FAU - Gudelsky, G A
AU  - Gudelsky GA
AD  - Department of Psychiatry, School of Medicine, Case Western Reserve University, 
      Cleveland, OH 44106.
FAU - Yamamoto, B K
AU  - Yamamoto BK
FAU - Nash, J F
AU  - Nash JF
LA  - eng
GR  - DA 07427/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Amphetamines)
RN  - 0 (Methoxydimethyltryptamines)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OOM10GW9UE (4-iodo-2,5-dimethoxyphenylisopropylamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Amphetamines/administration & dosage/*pharmacology
MH  - Analysis of Variance
MH  - Animals
MH  - Corpus Striatum/*drug effects/metabolism
MH  - Dopamine/*metabolism
MH  - Injections, Subcutaneous
MH  - Male
MH  - Methoxydimethyltryptamines/administration & dosage/*pharmacology
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism
MH  - Serotonin Receptor Agonists/administration & dosage/*pharmacology
EDAT- 1994/11/03 00:00
MHDA- 1994/11/03 00:01
CRDT- 1994/11/03 00:00
PHST- 1994/11/03 00:00 [pubmed]
PHST- 1994/11/03 00:01 [medline]
PHST- 1994/11/03 00:00 [entrez]
AID - 0014-2999(94)90669-6 [pii]
AID - 10.1016/0014-2999(94)90669-6 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1994 Nov 3;264(3):325-30. doi: 10.1016/0014-2999(94)90669-6.